✨ Your Portfolio is fetched and updated from zerodha.
Small Chemicals
Market Cap
₹7,645 Cr.
P/E
17.68

Key Ratios

Market cap
Market cap
7,645 Cr
PE
PE
17.68
Prom Holding
Prom Holding
68.83 %
ROE (%)
ROE (%)
18.78
ROCE (%)
ROCE (%)
22.31
Div Yield (%)
Div Yield (%)
0.34
Sales
Sales
2,505 Cr
OPM (%)
OPM (%)
27.85 %
Debt to Equity
Debt to Equity
0.31

About

Epigral Limited (Formerly known as Meghmani Finechem Limited) is primarily engaged in manufact… Read more
Low
1502
52W Range
High
2407
  • Epigral
  • DCM Shriram
  • Guj. Alkalies & Chem

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statement

New
Edit rows

Forensics

11 Yes

Positive for this company

1 Neutral

Neutral for this company

4 No

Negative for this company

1 No Data

Insufficient data to analyse

Market Share

0 %
(as of Mar 22)
Chlor-Alkalis - Market Share

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Asset Break-Up

Operational Metrics

    Select a Metric
    • Capacity Utilization - Chemicals (%)
    • Manufacturing Capacity - Caustic Soda (MTPA)
    • Realization / Tonne - Caustic Soda (Rs/MT)
    • Manufacturing Capacity - Chloromethanes (MTPA)
    • Manufacturing Capacity - Hydrogen Peroxide (MTPA)
    • Capacity Utilization - Chlor-Alkali (%)
    • Manufacturing Capacity - Caustic Potash (MTPA)
    • Manufacturing Capacity - CPVC Resin (MTPA)

    Peer Comparison

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    FAQs on Epigral Ltd. Business

    Epigral Limited, formerly known as Meghmani Finechem Limited, is a leading ISO-certified company manufacturing and selling Chlor Alkali & its Derivatives with backward and forward integration facilities.

    Epigral major competitors are DCM Shriram, Guj. Alkalies & Chem, TGV SRACC, Chemfab Alkalis, TN Petro Products, Primo Chemicals, Lords Chloro Alkali.
    Market Cap of Epigral is ₹7,668 Crs.
    While the median market cap of its peers are ₹922 Crs.

    Epigral seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material